evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

185 questions · 186 findings · 5 reviews · Common Mental Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 10 · 5.4%GRADE not reported 16 · 8.6%Very low 23 · 12.4%Low 38 · 20.4%Moderate 98 · 52.7%High 1 · 0.5%

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

Leaving the study early · treatment‐resistant depression in adults

Augmentation of current antidepressant (fluoxetine 20 mg/d) with… showed no clear difference in dropouts compared with augmentation of current antidepressant (fluoxetine 20 mg/d) with… (low certainty).

1 finding from 1 review

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

Proportions of participants responding to treatment ≥ 50% reduction in depression score from baseline to end of treatment. A larger RR indicates greater response to treatment in the SAMe group · treatment‐resistant depression in adults

Augmentation of current antidepressant (fluoxetine 20 mg/d) with… may leads to higher response (≥ 50% reduction in HAM‐D score) compared with augmentation of current antidepressant (fluoxetine 20 mg/d) with… (low certainty).

1 finding from 1 review

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

Remission · treatment‐resistant depression in adults

Augmentation of current antidepressant (fluoxetine 20 mg/d) with… may leads to higher remission (HAM‐D total score ≤ 7) compared with augmentation of current antidepressant (fluoxetine 20 mg/d) with… (low certainty).

1 finding from 1 review

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo

Depressive symptoms · treatment‐resistant depression in adults
2 findings from 1 review

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo

Leaving the study early · treatment‐resistant depression in adults

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60… showed no clear difference in dropouts compared with augmentation of current antidepressant (fluoxetine 20 mg/d to 60… (low certainty).

1 finding from 1 review

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo

Proportions of participants responding to treatment ≥ 50% reduction in depression score from baseline to end of treatment. A larger RR indicates greater response to treatment in the SAMe group · treatment‐resistant depression in adults

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60… showed no clear difference in response (≥50% reduction in MADRS score) compared with augmentation of current antidepressant (fluoxetine 20 mg/d to 60… (low certainty).

1 finding from 1 review

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo

Remission ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review